Molecular Identity Developer Eli Lilly Mechanism Triple GLP-1, GIP, and glucagon receptor agonist FDA Status Under regulatory review (Phase 3 complete) Administration Weekly subcutaneous Triple-Agonist Mechanism Retatrutide combines all pathways: GLP-1: Core incretin signaling (shared with both Mazdutide and Tirzepatide) GIP: Second incretin pathway (shared with Tirzepatide, absent in Mazdutide) Glucagon: Hepatic energy expenditure (shared with Mazdutide, absent in Tirzepatide) For research examining the contributions of all three pathways, Retatrutide provides comprehensive coverage
Always discuss any unusual symptoms or side effects with your healthcare professional to ensure safe and effective treatment.
Here we focus on three that affect cognitive function
Fat redistribution : I often use fat transfer techniques, taking surplus fat from another area of the body and reinjecting it into the face
Zakrzewska E, Zegan M, Michota-Katulska E (2015) Dietary recommendations in hypothyroidism with coexistence of Hashimotos disease
And for some foods, the shift goes the other direction